A Long-term Cohort Study of Nonsteroidal Anti-inflammatory Drug Use and Disease Activity in Outpatients with Inflammatory Bowel Disease

Abstract

Use of low-dose NSAIDs was not associated with an increase in disease activity for these outpatients with either CD or UC. Use of high-doses of NSAIDs was associated with a higher numerical disease activity index score among CD patients with colonic involvement, but this was not reflected by an increase in significant disease flares.

Guidelines for the management of ulcerative colitis. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology

“…W wybranych przypadkach zaleca się również miejscowe iniekcje ze steroidu, a także fizjoterapię. Sulfasalazyna może być stosowana, zwłaszcza w podtypie 1 obwodowego zapalenia stawów [8,132,133].…”

Guidelines for the management of Crohn’s disease. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology

“…W wybranych przypadkach zaleca się również miejscowe iniekcje ze steroidu, a także fizjoterapię. Sulfasalazyna może być stosowana, zwłaszcza w podtypie 1 obwodowego zapalenia stawów [2,151,152].…”

Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?

“…In some patients, exacerbation disease exacerbation happens; however, it is uncertain whether NSAIDs are implicated in IBD relapse or whether COX-2 inhibitors are safer than NSAIDs. NSAIDs have been implicated in the onset or the exacerbation of IBD in a number of studies and case reports [13,14], whereas in other studies, no relationship has been found between NSAID treatment and an increase in significant disease flares [15,16]. On the other hand, COX-2 inhibitors have a smaller incidence of toxicity to the small bowel or colon [10], as recent studies indicate that COX-2 inhibitors are prescribed more often than NSAIDs in patients who are older, sicker, and have risk factors associated with NSAID gastropathy [17].…”